Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1/2 2Phase 2 1

Status

Completed 4Terminated 1

Sponsor Class

OTHER 3INDUSTRY 2

Study Type

Interventional 5

Sponsor

Cancer Type

Genitourinary 5

Conditions

Breast Neoplasms 1934Neoplasms 1387Carcinoma, Non-Small-Cell Lung 1328Prostatic Neoplasms 1072Multiple Myeloma 857Leukemia, Myeloid, Acute 764Neoplasm Metastasis 693Colorectal Neoplasms 679Melanoma 671Lung Neoplasms 666Lymphoma 656Leukemia 592Lymphoma, Non-Hodgkin 588Leukemia, Lymphocytic, Chronic, B-Cell 529Ovarian Neoplasms 522Pancreatic Neoplasms 493Precursor Cell Lymphoblastic Leukemia-Lymphoma 473Recurrence 466Myelodysplastic Syndromes 422Lymphoma, Follicular 407Head and Neck Neoplasms 402Carcinoma, Renal Cell 377Glioblastoma 376Lymphoma, Large B-Cell, Diffuse 372Brain Neoplasms 371Hodgkin Disease 352Carcinoma, Hepatocellular 325Squamous Cell Carcinoma of Head and Neck 323Lymphoma, Mantle-Cell 302Sarcoma 281

Interventions

radium Ra 223 dichloride 1Everolimus 1Denosumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Interventional × Has results × Hormone Refractory Prostate Cancer × Clear all
NCT00699751 2026-02-23

ALSYMPCA

Bayer

Phase 3 Completed
921 enrolled 43 charts
Genitourinary

Hormone Refractory Prostate Cancer

NCT00286091 2018-10-17

Study on Prolonging Bone Metastasis-Free Survival in Men With Hormone Refractory Prostate Cancer

Amgen

Phase 3 Completed
1,435 enrolled 15 charts
Genitourinary

Hormone Refractory Prostate Cancer

NCT00928252 2017-08-14

Chemotherapy Response Monitoring With 18F-choline PET/CT in Hormone Refractory Prostate Cancer

Queen's Medical Center

Phase 1/2 Completed
25 enrolled 9 charts
Genitourinary

Hormone Refractory Prostate Cancer

NCT00629525 2015-03-03

RAD001 in Patients With Metastatic, Hormone-Refractory Prostate Cancer

Duke University

Phase 2 Completed
35 enrolled 6 charts
Genitourinary

Hormone Refractory Prostate Cancer

NCT00906243 2012-04-04

RNActive®-Derived Therapeutic Vaccine

University of Florida

Phase 1/2 Terminated
6 enrolled 5 charts
Genitourinary

Hormone Refractory Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡